Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
Foundation Fighting Blindness
New Zealand